de Snoo FA, Riedijk SR, van Mil AM, Bergman W, Ter Huurne JA, Timman R,
Bertina W, Gruis NA, Vasen HF, van Haeringen A, Breuning MH, Tibben A. Genetic testing in familial melanoma: uptake and implications. Psychooncology. 2008 Jul 9.
Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, Henders
AK, Homer N, Campbell MJ, Stark M, Thomas S, Schmid H, Holland EA, Gillanders EM,
Duffy DL, Maskiell JA, Jetann J, Ferguson M, Stephan DA, Cust AE, Whiteman D,
Green A, Olsson H, Puig S, Ghiorzo P, Hansson J, Demenais F, Goldstein AM, Gruis
NA, Elder DE, Bishop JN, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper
JL, Martin NG, Trent JM, Mann GJ, Hayward NK.
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet. 2008 Jul; 40(7): 838-40.
de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, van
der Drift C, van Leeuwen I, van Mourik L, Huurne JA, Frants RR, Willemze R,
Breuning MH, Trent JM, Gruis NA.
Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum Genet. 2008 Apr 9.
Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C,
Gruis N, Ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi
MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT,
Newton Bishop J; members of GenoMEL, the Melanoma Genetics Consortium.
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium
(GenoMEL).
Eur J Cancer. 2008 Jun; 44(9): 1269-1274.
Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal
melanoma.
Invest Ophthalmol Vis Sci. 2008 Apr; 49(4): 1291-8.
Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1): 23-7.
Smit NP, van Nieuwpoort FA, Marrot L, Out C, Poorthuis B, van Pelt H, Meunier
JR, Pavel S.
Increased melanogenesis is a risk factor for oxidative DNA damage--study on
cultured melanocytes and atypical nevus cells. Photochem Photobiol. 2008 May-Jun; 84(3): 550-5.
Newton Bishop JA, Gruis NA. Genetics: what advice for patients who present with a family history of melanoma? Semin Oncol. 2007 Dec;34(6):452-9. Review.
Zuidervaart W, Pavey S, van Nieuwpoort FA, Packer L, Out C, Maat W, Jager MJ,
Gruis NA, Hayward NK.
Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res. 2007 Dec; 17(6): 380-6.
Bergman W, Gruis NA. Phenotypic variation in familial melanoma: consequences for predictive DNA
testing
Arch Dermatol. 2007 Apr;143(4):525-6.
de Snoo FA, Kroon MW, Bergman W, ter Huurne JA, Houwing-Duistermaat JJ, van
Mourik L, Snels DG, Breuning MH, Willemze R, Frants RR, Gruis NA.
From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in
sporadic atypical nevus patients J Am Acad Dermatol. 2007 May ;56(5): 748-52. Epub 2007 Feb 5.
Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ,
Gruis NA.
Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 2007 Feb; 48(2): 486-90.
Koynova DK, Jordanova ES, Milev AD, Dijkman R, Kirov KS, Toncheva DI, Gruis
NA.
Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to
refine the region of chromosome 20q amplification in melanoma.
Melanoma Res. 2007 Feb; 17(1): 37-41.
Seminara D, Khoury MJ, O'Brien TR, Manolio T, Gwinn ML, Little J, Higgins JP,
Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP,
Chokkalingam AP, Danesh J, Davey Smith G, Dolan S, Duncan R, Gruis NA, Hashibe M,
Hunter D, Jarvelin MR, Malmer B, Maraganore DM, Newton-Bishop JA, Riboli E,
Salanti G, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM,
Zimmern R, Ioannidis JP
Human Genome Epidemiology Network; the Network of
Investigator Networks.
The emergence of networks in human genome epidemiology: challenges and
opportunities.
Epidemiology. 2007 Jan; 18(1): 1-8. No abstract available.
PMID: 17179752
Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi
E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D,
Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D,
Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM,
Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S,
Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E;
Melanoma Genetics Consortium (GenoMEL).
High-risk melanoma susceptibility genes and pancreatic cancer, neural system
tumors, and uveal melanoma across GenoMEL.
Cancer Res. 2006 Oct 15; 66(20): 9818-28.
Koynova D, Jordanova E, Kukutsch N, van der Velden P, Toncheva D, Gruis N. Increased C-MYC copy numbers on the background of CDKN2A loss is associated with
improved survival in nodular melanoma. J Cancer Res Clin Oncol. 2007 Feb;133(2):117-23. Epub 2006 Sep 15.
Zuidervaart W, Hensbergen PJ, Wong MC, Deelder AM, Tensen CP, Jager MJ, Gruis NA. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3): 786-93.
de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett. 2005 Dec 18; 230(2): 153-86. Review.
van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol. 2005 Oct; 32(5): 479-87. Review.
Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM,Pavey S, van der Velden P, Out C, Jager MJ, Hayward NK, Gruis NA. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005 Jun 6;92(11):2032-8.
Riedijk SR, de Snoo FA, van Dijk S, Bergman W, van Haeringen A, Silberg S,van Elderen TM, Tibben A. Hereditary melanoma and predictive genetic testing: why not? Psychooncology. 2005 Sep; 14(9): 738-45.
van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA,van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.J Clin Oncol. 2005 Jun 10; 23(17): 3886-96. Epub 2005 May 16.
van Dinten LC, Pul N, van Nieuwpoort AF, Out CJ, Jager MJ, van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):24-30. PMID: 15623750 [PubMed - indexed for MEDLINE]
Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med. 2004 Mar 15; 36(6): 782-801.
Pavel S, van Nieuwpoort F, van der Meulen H, Out C, Pizinger K, Cetkovska P, Smit NP, Koerten HK. Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi. Eur J Cancer. 2004 Jun; 40(9): 1423-30.
Hayes MJ, Koundouris A, Gruis N, Bergman W, Peters GG, Sinclair AJ. P16(INK4A)-independence of Epstein-Barr virus-induced cell proliferation and virus latency. J Gen Virol. 2004 Jun; 85(Pt 6): 1381-6.
van Nieuwpoort F, Smit NP, Kolb R, van der Meulen H, Koerten H, Pavel S. Tyrosine-induced melanogenesis shows differences in morphologic and melanogenic preferences of melanosomes from light and dark skin types. J Invest Dermatol. 2004 May; 122(5): 1251-5.
Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, Frants RR, Jager MJ, Gruis NA. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer. 2003 Nov 17; 89(10): 1914-9.
de vos tot Nederveen Cappel WH, Offerhaus GJ, van Puijenbroek M, Caspers E,Gruis NA, De Snoo FA, Lamers CB, Griffioen G, Bergman W, Vasen HF, Morreau H. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1): 3598-605.
Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT,Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN,Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J; Lund Melanoma Study Group; Melanoma Genetics Consortium. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003,73:301-13.
Pavel S, Smit NP, van der Meulen H, Kolb RM, de Groot AJ, van der Velden PA,Gruis NA, Bergman W. Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case. Melanoma Res. 2003 Apr; 13(2): 171-8.
Hoogduijn MJ, Smit NP, van der Laarse A, van Nieuwpoort AF, Wood JM, Thody
AJ. Melanin has a role in Ca2+ homeostasis in human melanocytes. Pigment Cell Res. 2003 Apr; 16(2): 127-32.
PMID: 12622789 [PubMed - indexed for MEDLINE]
Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N,Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA; Melanoma Genetics Consortium.
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002,94:894-903.
Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 2002,21:2936-45.
Kennedy C, Naipal A, Gruis NA, Struijk L, ter Schegget J, Willemze R, Claas FH, Bouwes Bavinck JN, Doxiadis II. MICA gene polymorphism is not associated with an increased risk for skin cancer. J Invest Dermatol. 2002,118:686-91.
Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol. 2001, 117:294-300.
van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001, 69:774-9.
Bastiaens M, ter Huurne J, Gruis N, Bergman W, Westendorp R, Vermeer BJ,Bouwes Bavinck JN. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet. 2001, 10:1701-8.
van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001, 61:5303-6.
Bastiaens MT, Struyk L, Tjong-A-Hung SP, Gruis N, ter Huurne J, Westendorp RG, Vermeer BJ, Bavinck JN, ter Schegget J. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog. 2001, 30:56-61.
Bastiaens MT, ter Huurne JA, Kielich C, Gruis NA, Westendorp RG, Vermeer BJ, Bavinck JN; Leiden Skin Cancer Study Team.
Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet. 2001, 68:884-94.
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000, 87:809-11.
Dekker SK, van Doorn R, Kempenaar J, Gruis NA, Vermeer BJ, Ponec M. Skin equivalent: an attractive model to evaluate early melanoma metastasis. Melanoma Res. 2000, 10:127-40.
van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. Genome Res. 1999,9:575-80.
Snels DG, Hille ET, Gruis NA, Bergman W. Risk of cutaneous malignant melanoma in patients with nonfamilial atypical nevi from a pigmented lesions clinic. J Am Acad Dermatol. 1999, 40:686-93.
